FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 347:1376-1377 October 24, 2002 Number 17 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited Related Article by Rosenwald, A. PubMed Citation

To the Editor: With the use of gene profiling in patients with diffuse large-B-cell lymphoma, Rosenwald et al. (June 20 issue)¹ found that overall survival after anthracycline-based chemotherapy differed significantly among the three gene-expression subgroups they identified. Was this finding based on a comparison of the germinal-center B-cell–like subgroup with the type 3 subgroup and with the activated B-cell–like subgroup, or on a comparison of the germinal-center B-cell–like subgroup with the other two subgroups combined? Figure 2 of the article by Rosenwald et al. ranks patients in quartiles 1, 2, 3, and 4, with five-year survival rates of 73, 71, . . . [Full Text of this Article]

This article has been cited by other articles:

• Ross, J. S., Kallakury, B. V. S., Sheehan, C. E., Fisher, H. A. G., Kaufman, R. P. Jr., Kaur, P., Gray, K., Stringer, B. (2004). Expression of Nuclear Factor-{kappa}B and I{kappa}B{alpha} Proteins in Prostatic Adenocarcinomas: Correlation of Nuclear Factor-{kappa}B Immunoreactivity with Disease Recurrence. Clin. Cancer Res. 10: 2466-2472 [Abstract] [Full Text]